Release – Comstock Mining (LODE) – Announces 2021 Annual Meeting of Shareholders and Record Date


Comstock Announces 2021 Annual Meeting of Shareholders and Record Date

 

Virginia City, NV (March 25, 2021) – Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) announces that the 2021 Annual Meeting of Shareholders is scheduled for Thursday, June 3, 2021, at the historic Gold Hill Hotel in Gold Hill, Nevada. The meeting will begin at 9:00 a.m. Pacific Time and will include an update on the Company’s corporate portfolio, geological developments and clean energy technologies.

The 2021 Annual Meeting schedule for June 3, 2021, is as follows:

8:00 am – 9:00 am   Continental Breakfast
9:00 am – 12:00 pm  2021 Annual Shareholders Meeting, Company Presentations, Q & A
12:00pm – 1:00 pm   Lunch will be served at the Gold Hill Hotel following the meeting
1:00 pm – 4:00 pm   Portfolio Investment Showcases (Comstock, LiNiCo, MCU & Sierra Springs)

For the convenience of Shareholders, they may view the Annual Meeting live via a webcast. The link for the webcast will be included in shareholder materials as well as posted on our website in the investors section.

Due to COVID-19 guidelines set by the State of Nevada and Storey County, seating is limited for Shareholders and is based on a first-come, first-served basis by registering at the Company website:
https://www.comstockmining.com/investors/asm2021/

The record date for the Annual Meeting is April 6, 2021. Only shareholders of record at the close of business on April 6, 2021, may vote at the meeting. The Company’s proxy statement will be sent to shareholders of record and will describe the matters to be voted upon.

About Comstock Mining Inc.

Comstock Mining Inc. is an emerging leader in sustainable, mineral development and production of environment-enhancing, increasingly scarce strategic and precious metals, focused on conservation-based waste, high-value, cash-generating, mineral and metals essential to meeting the rapidly increasing demand for clean energy technologies. The Company has extensive, contiguous property in the historic, world-class Comstock and Silver City mining districts (collectively, the “Comstock District”) with fully permitted, metallurgical labs and an operational, mineral processing and beneficiation platform that includes a growing portfolio of mercury remediation and gold extraction facilities. Additional information on Comstock is available online at www.comstockmining.com.

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: consummation of all pending transactions; project, asset or Company valuations; future industry market conditions; future explorations, acquisitions, investments and asset sales; future performance of and closings under various agreements; future changes in our exploration activities; future estimated mineral resources; future prices and sales of, and demand for, our products; future impacts of land entitlements and uses; future permitting activities and needs therefor; future production capacity and operations; future operating and overhead costs; future capital expenditures and their impact on us; future impacts of operational and management changes (including changes in the board of directors); future changes in business strategies, planning and tactics and impacts of recent or future changes; future employment and contributions of personnel, including consultants; future land sales, investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives; the nature and timing of and accounting for restructuring charges and derivative liabilities and the impact thereof; contingencies; future environmental compliance and changes in the regulatory environment; future offerings of equity or debt securities; asset sales and associated costs; future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, earnings and growth. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: counterparty risks; capital markets’ valuation and pricing risks; adverse effects of climate changes or natural disasters; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mining activities; contests over title to properties; potential dilution to our stockholders from our stock issuances and recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting businesses; permitting constraints or delays; decisions regarding business opportunities that may be presented to, or pursued by, us or others; the impact of, or the non-performance by parties under agreements relating to, acquisitions, joint ventures, strategic alliances, business combinations, asset sales, leases, options and investments to which we may be party; changes in the United States or other monetary or fiscal policies or regulations; interruptions in production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, cyanide, water, diesel fuel and electricity); changes in generally accepted accounting principles; adverse effects of terrorism and geopolitical events; potential inability to implement business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors or others; assertion of claims, lawsuits and proceedings; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the SEC; potential inability to list our securities on any securities exchange or market; inability to maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Contact information

Comstock Mining Inc.
117 American Flat Rd
PO Box 1118
Virginia City, NV 89440
http://www.comstockmining.com

Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
[email protected]

Zach Spencer
Director of External Relations
Tel (775) 847-5272 ext.151
[email protected]

Source: Comstock Mining

Research coverage of Comstock Mining (LODE) on Channelchek is provided by Noble Capital Markets, Inc. Please refer to the research disclosures on the most recent LODE report for more information.

One Stop Systems Inc. (OSS) – Steadily Improving Operating Environment

Friday, March 26, 2021

One Stop Systems Inc. (OSS)
Steadily Improving Operating Environment

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems. The product line of the company includes GPU Appliances, GPU Expansion, GPUs and co-processors, Flash storage arrays, Flash storage expansion, Servers, Disk Arrays, Desktop computing appliances, accessories and parts. The company delivers high-end technology to customers through the sale of equipment and software for use on their premises or through remote cloud access to secure data centres housing technology.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q20 Results. Fourth quarter revenue of $13.9 million, up 17% sequentially, down 24% y-o-y, and above guidance. Net income was $244,000, or $0.01 per share. On an adjusted EPS basis, 4Q20 diluted EPS was $0.04 versus diluted adjusted EPS of $0.07 for 4Q19. Although the top line exceeded our expectation, net income was below our projection. We were at $13.5 million of revenue and EPS of $0.05, while consensus was $13.2 million and $0.04, respectively.

    New Wins.  OSS added four new $1+ million wins in the quarter, increasing the total to 16 for the year, the same as in 2019, a strong accomplishment in a COVID impacted year, in our view. The 32 program wins over the past two years contributed $18 million to 2020 revenue, including $12 million from new customers …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

FAT Brands Inc. (FAT) – Solid 4Q as Operations Continue to Rebound

Friday, March 26, 2021

FAT Brands Inc. (FAT)
Solid 4Q as Operations Continue to Rebound

FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, and acquires predominantly fast casual restaurant concepts. The company provides turkey burgers, chicken Sandwiches, chicken tenders, burgers, ribs, wrap sandwiches, and others. Its brand portfolio comprises Fatburger, Buffalo’s Cafe and Express, and Ponderosa and Bonanza. The company’s overall footprint covers nearly 32 countries. Fatburger generates maximum revenue for the company.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q20 Results. Fat Brands reported 4Q20 revenue of $6.5 million, compared to $5.3 million in 4Q19. The increased revenue was driven by royalties, which rose to $4.7 million in the quarter from $3.8 million in 4Q19. Cost and expenses were impacted by a number of one-time items, which combined with higher interest expense resulted in a reported loss for the quarter of $7.67 million, or $0.64 per share, compared to a loss of $953,000, or $0.08 per share last year. We had projected revenue of $6 million and a net loss of $1.24 million, or $0.10 per share.

    Improving Trends and Pipeline.  Systemwide sales rose to $106.9 million, up from $72.2 million in the third quarter. Y-o-Y same store sales decline continued to improve, dropping to 9.4% in 4Q20, compared to down 13.2% in 3Q20. So far in 1Q21 weekly system-wide sales rose from $7.9 million in early January to $9.6 million in mid-March. In 4Q20, 29 new locations opened, increasing the full year total …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Allegiant Gold Allegiant Gold Ltd (AUXXF)(AUAU:CA) – Virtual Road Show Take-Aways

Friday, March 26, 2021

Allegiant Gold

Allegiant Gold Ltd (AUXXF)(AUAU:CA)
Virtual Road Show Take-Aways

Allegiant Gold Ltd is a gold exploration company. Its project profile consists of Bolo, Browns Canyon, Clara Moro, Four Metals, Monitor Hills, Red Hills, Silver Dome, West Goldfield, White Horse Flats, Mogollon, Eastside, Dutch Flat, and others.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Virtual roadshow presentation. Mr. Peter Gianulis, CEO, made a presentation and participated in a virtual roadshow. Replays will be available shortly on www.channelchek.com. Management believes that its flagship Eastside project represents a large gold resource in different pit areas that could potentially reach 2 to 5 million gold ounces. Near-term goals include proving up a resource of 1.5 to 2.0 million gold ounces within the next 12 months and then make decisions on how to expand those resources.

    Drilling program.  In September 2020, the company commenced a 15,000-meter drilling program to test additional targets, expand resources at the Castle Zone in the southern part of the project area, and increase resources in the original pit zone in the northern portion of the project area, which hosts a current mineral resource. By year-end 2020, Allegiant drilled roughly 6,000 meters in the …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Chakana Copper Corp (CHKKF)(PERU:CA) – Drilling at Huancarama Reveals Second High-Grade Discovery

Thursday, March 25, 2021

Chakana Copper Corp (CHKKF)(PERU:CA)
Drilling at Huancarama Reveals Second High-Grade Discovery

Noble Capital Markets research on Chakana Copper Corp is published under ticker symbols CHKKF and PERU:CA. The price target is in USD and based on ticker symbol CHKKF. Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the high-grade gold-copper-silver Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project consists of high-grade gold-copper-silver mineralization hosted in tourmaline breccia pipes. A total of 33,353 metres of drilling has been completed to-date, testing nine (9) of twenty-three (23) confirmed breccia pipes with more than 92 total targets. Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to several metals including copper, gold, and silver.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    High-grade breccia pipe discovery at Huancarama. Chakana Copper announced the discovery of a second high-grade breccia pipe within the Huancarama Breccia Complex at the Soledad Project in Peru. The new high-grade breccia pipe (Huancarama West) is only 75 meters west of the previously announced Huancarama East discovery. To date, a total of 33 diamond core holes have been completed within the Huancarama Breccia Complex to delineate the boundaries of the breccia pipes.

    Drill results highlight near-surface mineralization potential.  The company released results for six drill holes at Huancarama West and three drill holes at Huancarama East. Five of the six drill holes at Huancarama West intersected mineralized breccia starting at depths ranging from 2.75 to 4.0 meters with significant gold and silver intercepts. The three holes at Huancarama East confirmed that the …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Indonesia Energy Corp (INDO) – Rating Upgraded, PO Reinstated

Thursday, March 25, 2021

Indonesia Energy Corp (INDO)
Rating Upgraded, PO Reinstated

Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. It holds two oil and gas assets through its subsidiaries in Indonesia: one producing block (the Kruh Block) and one exploration block (the Citarum Block). The Kruh Block is located to the northwest of Pendopo, Pali, South Sumatra. The Citarum Block is located to the south of Jakarta.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    We are upgrading the shares of INDO following weakness in the share price. Recall that we had downgraded the shares on March 3rd when the share price crossed our price objective and traded above our P.O. for several weeks. The shares have been weak in recent weeks and now trade below our estimated fair value. As a result, we are upgrading the shares and reinstating our price objective.

    Stock value is not dependent on near-term energy pricing.  Our valuation work is based on a two-stage discounted cash flow analysis. In the case of INDO who has limited current production but large drilling plans, much of the company’s valuation is back-end loaded. When we downgraded the shares, we did so because they had risen based on near-term oil price strength even as our long-term oil price …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Pyxis Tankers Inc. (PXS) – Weak End to 2020, But Capital Raises Add Flexibility

Thursday, March 25, 2021

Pyxis Tankers Inc. (PXS)
Weak End to 2020, But Capital Raises Add Flexibility

Pyxis Tankers Inc is a United States-based international maritime transportation company which focuses on the product tanker sector. It owns a fleet which comprises of double hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Pyxis Epsilon, Pyxis Theta, Pyxis Malou, Pyxis Delta, Northsea Alpha, and Northsea Beta. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q2020 EBITDA Below Expectations. Adjusted 4Q2020 EBITDA of negative $0.2 million was below our estimate due to lower TCE revenue, higher opex and G&A expenses. Versus our estimate, TCE revenue of $3.58 million was $0.8 million lower and opex of $2.86 million was $0.3 million above. G&A expense of $0.61 million was slightly lower than expected by $0.1 million.

    Adjusting 2021 EBITDA estimates with potential 2H2021 rebound as the swing factor.  Our 2021 EBITDA estimate drops to $4.3 million from $4.5 million, which is based on TCE rates of $10,167/day and operating days of 1,611. With the quarter largely behind us, 1Q2021 forward cover on the MR fleet is 100% booked at an average rate of ~ $13.2k and 75% of available 2Q2021 available days are booked at …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Seanergy Maritime (SHIP) – 4Q2020 Results In Line. Expanding for Upturn

Thursday, March 25, 2021

Seanergy Maritime (SHIP)
4Q2020 Results In Line. Expanding for Upturn.

Seanergy Maritime Holdings Corp., an international shipping company, provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. Seanergy Maritime Holdings Corp. is the only pure-play Capesize shipping company listed in the US capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of 10 Capesize vessels, with total capacity of approximately 1,748,581 dwt and an average fleet age of about 9.8 years. The Company is incorporated in the Marshall Islands with executive offices in Athens, Greece and an office in Hong Kong. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP” and class A warrants under “SHIPW”.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q2020 Operating results were in line with expectations. Reported adjusted EBITDA of $8.3 million was in line with our expectations after adding back the one-time items from the costs of debt restructuring and refinancing. TEC revenue of $16.7 million was slightly higher than expected due to higher TCE rates of $16,511/day but was offset by higher opex of $6,132/day. Management fees were $276/day and G&A expenses were $1,902/day.

    Increasing 2021 EBITDA estimate to $51.0 million from $47.7 million to reflect 1Q2021 forward cover, current dry bulk market conditions and pending acquisitions.  Our estimate is based on TCE rates of $17,742/day, up from a previous estimate of $17,742/day with no change in ownership days of 4,613. With the quarter largely passed,1Q2021 forward cover was 98% booked at an average TCE rate of …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Are Small Cap Stocks Smart Investments?

 


Stimulus Checks, Taxes, and Investments

 

IRA tax season and the third round of stimulus checks are inspiring recipients to deploy their $1,400 stimulus to reduce their 2020 tax burden. A deposit in a qualified retirement account could minimize 2020 (or 2021) taxes and at the same time enhance retirement – or even help with home purchase options down the road. Getting the most benefit from investing these longer-term assets is dependent on many factors, including the individual’s time horizon. The following advice from a highly credentialled investment analyst may help inform investors’  allocation options.

Robert R. Johnson, Ph.D., CFA, CAIA, is a Professor of Finance at Heider College of Business, Creighton University. He is also a co-author of The Tools and Techniques Of Investment
Planning
, Strategic Value Investing, and Investment Banking for Dummies, among others. As if these credentials aren’t enough, he is the former deputy CEO of the CFA Institute and headed the CFA Program, as well as having been the President of the American College of Financial Services. Dr. Johnson is one of the most credentialed individuals in the field of finance and investment, so I asked him a question important to those that use Channelchek for insight on small and microcap investments. The answer is worth knowing for anyone that is more investment than trading-oriented.

Channelchek (PH): “Dr. Johnson, if over a long enough timeline, small-cap indices outperform large-cap. Could it stand to reason that if you’re a young saver for retirement, holding stocks that have demonstrated a greater return over time should have an allocation? Also, could individual stocks be more suitable than an ETF in the small-cap sector? What stipulations would you have for an investor buying small or even microcap stocks in their IRA?

Dr. Robert R. Johnson: You are absolutely correct in that small-cap stocks are most suitable for investors with a long time horizon. According to data by Duff & Phelps [formerly Ibbotson Associates] from 1926 through 2019, an index of small-cap stocks returned 11.9% compounded annually, while large-cap stocks returned 10.2% compounded annually. While that may not sound like much of a difference, one dollar invested in a large-cap index would have grown to $9,243 at year-end 2019. That same dollar invested in a small-cap index would have grown to $39,381 at year-end 2019. Now, those higher long-term returns come at a cost of higher volatility. Over that same time period, the standard deviation of annual returns was 19.8% for the large-cap index and 31.5% for the small-cap index.

 

“…one dollar invested in a large-cap index would have grown to $9,243 at year-end 2019. That same dollar invested in a small-cap index would have grown to $39,381 at year-end 2019.” – Robert R. Johnson, PhD, CFA, CAIA

 

Individuals need to be taught to invest for retirement and not to save for retirement. The surest way to build true long-term wealth for retirement is to invest in the stock market. Starting early is the key to successfully building wealth because of the effect of compound interest. Albert Einstein said that “compound interest is the greatest mathematical discovery of all time.” Time is the greatest ally of the investor because of the “magic” of compound interest. An IRA is the perfect investment vehicle for an individual with a long time horizon. They can weather the increased volatility of the small-cap universe.

People in their 20s should begin investing in a low-fee, diversified small-cap equity index fund and continue to invest consistently whether the market is up, down, or sideways. Dollar-cost averaging into an index mutual fund or ETF is a terrific lifelong strategy. Dollar-cost averaging is a simple technique that entails investing a fixed amount of money in the same fund or stock at regular intervals over a long period of time.

Additionally, these investors should be 100% invested in stocks and have no bond exposure. Ironically, one of the biggest mistakes young investors make is taking too little risk, not too much risk.

 

“…often that is what happens to beginning investors who buy the stock of the company they work for or the stock of a product they like. When they experience failure, they withdraw from the equity markets. Investing in a broadly diversified basket of securities is a prudent strategy.” – Robert R. Johnson, PhD, CFA, CAIA

 

For the vast majority of investors, the KISS mantra — keep It simple, stupid — should guide their investment philosophy. The idea behind index investing is “if you can’t beat ‘em, join ‘em.” Investors simply can’t afford to make oversized bets on individual securities. And, often that is what happens to beginning investors who buy the stock of the company they work for or the stock of a product they like. When they experience failure, they withdraw from the equity markets. Investing in a broadly diversified basket of securities is a prudent strategy. An interesting study done by University of Arizona professor Hendrick Bessembinder shows that only four percent of common stocks have provided a higher return than Treasury bills. In other words, the returns on the market have been driven by a small percentage of big winners. Trying to pick winners, for most, is a loser’s game. The solution is to invest in diversified funds and you don’t need to pick those winners.”

Take-Away

There is debate whether today’s popular cap-weighted indices represent diversification relative to a well-selected, large diversified basket of a more even weighting. A previous Channechek article is provided below that discusses this concern; it was published before the 2020 explosion of tech stocks. Last year’s uneven growth reduced their diversification even more. Investors should evaluate if the current imbalance of individual index funds is now in fact making an oversized bet. 

Professor Robert R. Johnson, Ph.D., CFA, CAIA, certainly feels strongly that there is a difference between savings and investing. Bank accounts, CDs, bonds and notes are not the path for true long-term wealth. IRAs, 401ks and other funds earmarked for retirement should be in equities if you are not soon expected to live off those funds. For those that have a longer time horizon, accepting the higher volatility of small-cap stocks for the higher probable returns could be viewed as most prudent.

 

Paul Hoffman

Managing Editor, Channelchek

Suggested Reading:


Investment Barriers Once Seen Insurmountable are Falling Taking Stock of Index Funds



Large-Cap and Small-Cap Return Probabilities Company Sponsored Research/Small-Cap Stocks


Stay up to date. Follow us:

           


Stay up to date. Follow us:

QuickChek – March 25, 2021



Esports Entertainment Group Signs Multi-Year Deal with Denver Broncos

Esports Entertainment signed a multi-year partnership with the Denver Broncos to be the NFL franchise’s esports tournament provider

Research, News & Market Data on Esports Entertainment

Watch recent presentation from NobleCon17



Enochian BioSciences up in early trading on Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy

Enochian BioSciences reported that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months.

Research, News & Market Data on Enochian BioSciences




Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update

Ayala Pharmaceuticals reported financial results for the full year ended December 31, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs.

Research, News & Market Data on Ayala Pharmaceuticals

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Release – Ayala Pharmaceuticals (AYLA) – Reports Full Year 2020 Financial Results and Provides Business Update


Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update

 

– Completed $25 Million Strategic Financing; Extending Cash Runway into
2023

            – Accelerated Development of AL102 Desmoid Tumor Program
into Phase 2/3 Pivotal Trial

– On Track to Report Multiple Milestones in
2021 Across Clinical-Stage Pipeline

REHOVOT, Israel & WILMINGTON, Del., March 25, 2021 – (GLOBE NEWSWIRE) – Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today reported financial results for the full year ended December 31, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs.

“We are pleased with all that we were able to accomplish in 2020 despite the ongoing challenges of the COVID-19 pandemic, keeping clinical execution and patient and employee safety at the forefront of our everyday work. In 2020, we announced encouraging new data from the Phase 2 ACCURACY study of AL101 in R/M ACC, demonstrating initial safety and efficacy for the 4mg monotherapy cohort and we look forward to reporting additional data, including new 6mg cohort results from this program later this year,” said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. “With a strong foundation built in 2020, we have already achieved significant milestones across our broader pipeline in 2021 with the first patient dosing in our Phase 2 TENACITY trial in TNBC, accelerated development pathway and pivotal trial design for AL102 in desmoid tumors, as well as our $25 million strategic financing. We look forward to continuing this momentum with several key clinical milestones expected during the remainder of this year, including two new trial initiations and interim data readouts.”

Business and Clinical Highlights

  • Completed $25 million
    Strategic Financing:
    In February 2021, Ayala announced a $25 million strategic financing with investors including Redmile Group and SIO Capital Management, extending its cash runway into 2023.
  • Dosed First Patient in
    Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of
    Notch-Activated Triple Negative Breast Cancer:
    In January 2021, Ayala announced the dosing of the first patient in the Phase 2 TENACITY clinical trial of its potent, selective small molecule, AL101, for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer (TNBC).
  • Accelerated Development
    of AL102 for the Treatment of Desmoid Tumors with Pivotal Trial:
    In January 2021, Ayala announced that based on its end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) on AL102 for the treatment of desmoid tumors, and data from AL101 and AL102 Phase 1 studies
    including durable responses observed in patients with desmoid tumors,
    the FDA agreed to advance the program into a Phase 2/3 pivotal trial.
  • Presented Updated Positive Interim Data from Phase 2 ACCURACY Study of AL101 for the
    Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma at European
    Society for Medical Oncology (ESMO) Virtual Congress 2020:
    In September 2020, Ayala presented updated interim data from the 4mg cohort of its ongoing Phase 2 ACCURACY study of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) harboring Notch activating mutations, demonstrating meaningful clinical activity of AL101 4mg monotherapy with a 68% disease control rate across 40 evaluable patients. Partial responses were observed in six subjects (15%) and stable disease was observed in 21 subjects (53%).

 

Upcoming Milestones

  • On Track to Initiate Phase 2/3 Pivotal RINGSIDE Clinical Trial of AL102 for the
    Treatment of Desmoid Tumors:
    Ayala expects to initiate the pivotal RINGSIDE clinical trial of AL102 in adult and adolescent patients with desmoid tumors in the first half of 2021. Ayala expects an
    initial interim data read-out from part A and dose selection by mid-2022 with part B of the study
    commencing immediately thereafter
    .
  • Patient
    Enrollment in 6mg Cohort of Phase 2 ACCURACY Study Ongoing:
    Ayala continues to enroll patients in the 6mg cohort of the Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC, which will contain up to 42 subjects. The Company expects to provide further trial progress updates, including additional data, in the second half of 2021.
  • TENACITY Preliminary Data to be Reported in 2021: Ayala expects to report preliminary data from the recently initiated Phase 2 TENACITY clinical trial of AL101 for the treatment of R/M TNBC in the second half of 2021.

 

Full Year 2020 Financial Results

  • Cash Position: Cash and cash equivalents were $42.4 million as of December 31, 2020,
    as compared to $16.8 million
    as of December 31, 2019. The increase in cash and cash equivalents was primarily due to Ayala’s initial public offering in May 2020.
  • Collaboration Revenue: Collaboration revenue was $3.7 million for the full year of 2020, as compared to $2.3 million for the same period in 2019. The increase was primarily attributable to the advancement of Ayala’s
    collaboration with Novartis in 2020.
  • R&D Expenses: Research and development expenses were $22.4 million for the full year 2020, compared to $14.4 million for the same period in 2019. The increase was primarily driven by an increase in expenses in connection with the advancement of the clinical trials in ACC and TNBC.
  • G&A Expenses: General and administrative expenses were $7.4 million for the full year 2020, compared to $4.3 million for the same period in 2019. The increase was primarily related to increased costs in connection with becoming a publicly traded company in 2020.
  • Net Loss: Net loss was $30.1 million for the full year 2020, resulting in a basic net loss per share of $3.06 and a diluted net loss per share of $3.06. Net loss was $17.8 million for the same period in 2019, resulting in a basic net loss per share of $3.57 and a diluted net loss per share of $3.57.

 

Financial Guidance

Ayala expects its existing cash balance to fund operating expenses and capital expenditure requirements through multiple potential key clinical and development milestones into 2023.

 

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala’s lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE). For more information, visit www.ayalapharma.com.

 

Contacts:

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
[email protected]

Ayala Pharmaceuticals:
+1-857-444-0553
[email protected]

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements relating to our development of AL101 and AL102, the promise and potential impact of our preclinical or clinical trial data, the timing of and plans to initiate additional clinical trials of AL101 and AL102, upcoming milestones, including without limitation the timing and results of any clinical trials or readouts, patient enrollment and the sufficiency of cash to fund operations. These forward-looking statements are based on management’s current expectations. The words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our cash runway; our limited operating history and the prospects for our future viability; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our requirement to pay significant payments under product candidate licenses; the approach we are taking to discover and develop product candidates and whether it will lead to marketable products; the expense, time-consuming nature and uncertainty of clinical trials; enrollment and retention of patients; potential side effects of our product candidates; our ability to develop or to collaborate with others to develop appropriate diagnostic tests; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us. These and other important factors discussed under the caption “Risk Factors” in our
Annual
Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (SEC) on March 24, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

 
AYALA PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)
 
    December 31,
2019
    December 31,
2020
 
Assets                
Current Assets:                
Cash and Cash Equivalents   $ 16,725     $ 42,025  
Short-Term Restricted Bank Deposits     83       90  
Trade Receivables     469       681  
Prepaid Expenses and Other Current Assets     417       1,444  
Total Current Assets     17,694       44,240  
Long-Term Assets:                
Other Assets     283       305  
Deferred Offering Costs     656        
Property and Equipment, Net     1,421       1,283  
Total Long-Term Assets     2,360       1,588  
Total Assets   $ 20,054     $ 45,828  
Liabilities, Convertible Preferred Stock, and Stockholders’ (Deficit) Equity:                
Current Liabilities:                
Trade Payables   $ 2,922     $ 3,726  
Other Accounts Payables     2,380       3,151  
Total Current Liabilities     5,302       6,877  
Long-Term Liabilities:                
Long-Term Rent Liability     299     $ 553  
Total Long-Term Liabilities   $ 299     $ 553  
Convertible Preferred Stock, $0.01 par value:                
Series A Preferred Stock of $0.01 par value per share; 3,700,000 shares authorized at December 31, 2019; 3,679,778 issued and outstanding shares at December 31, 2019; aggregate liquidation preference value of $23,919 at December 31, 2019     23,823        
Series B Preferred Stock of $0.01 par value per share; 4,500,000 shares authorized at December 31, 2019; 3,750,674 issued and outstanding shares at December 31, 2019, respectively; aggregate liquidation preference value of $29,668 at December 31, 2019     29,550        
     Total Convertible Preferred Stock     53,373        
Stockholders’ (Deficit) Equity:                
Common Stock of $0.01 par value per share; 20,000,000 and 200,000,000 shares authorized at December 31, 2019 and 2020, respectively; shares issued at December 31, 2019 and 2020, respectively; 4,998,874 and 12,728,446 shares outstanding at December 31, 2019 and 2020, respectively   $ 51     $ 128  
Additional Paid-in Capital     1,770       109,157  
Accumulated Deficit     (40,741 )     (70,887 )
Total Stockholders’ (Deficit) Equity     (38,920 )     38,398  
Total Liabilities, Convertible Preferred Stock, and Stockholders’ (Deficit) Equity   $ 20,054     $ 45,828  


 
AYALA PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except shares and per shares data)
 
    Year ended
December 31,
2019
    Year ended
December 31,
2020
 
Revenue from License Agreement   $ 2,334     $ 3,708  
Cost of Revenue     (1,285 )     (3,708 )
Gross Profit     1,049        
Research and Development   $ 14,424     $ 22,406  
General and Administrative     4,336       7,371  
Operating Loss     (17,711 )     (29,777 )
Financial Income, Net     225       56  
Loss before Income Tax     (17,486 )     (29,721 )
Taxes on Income     (306 )     (425 )
Net Loss attributable to Common Stockholders   $ (17,792 )   $ (30,146 )
Net Loss per Share attributable to Common Stockholders, Basic and Diluted   $ (3.57 )   $ (3.06 )
Weighted Average Shares Used to Compute Net Loss per Share, Basic and Diluted     4,979,606       9,860,610  

Source: Ayala Pharmaceuticals

Top Ten Cryptocurrencies by Transactions


Top Ten Cryptocurrencies by Transactions

 

Bitcoin, Etherium, Dogecoin, we see these names daily. But, we may not have our bearings on the amount of exchange that occurs on each of the top ten cryptocurrencies. Liquidity is important in deciding whether you want to transact in any asset. Or, in this case, exchange with any asset. If there is not a buyer on the other side when you decide there is a better place for your wealth, then you can’t easily benefit from the value that you believe you hold.

We put together a table for your consumption of the top ten digital currencies by volume exchanged along with other useful data so you may compare, contrast, and develop a better grasp of the size of the market and the individual currencies activity.

 

Cryptocurrencies Ranked by Average 3-Month Volume

Symbol

Currency Name

Last Price

Volume

Avg Vol (3 month)

Circulation

USDT-USD

Tether

$ 1.001

95.73B

109.12B

39.71B

BTC-USD

Bitcoin

$ 55,386.970

62.14B

66.91B

1,033.63B

ETH-USD

Ethereum

$ 1,715.882

25.60B

31.86B

197.61B

LTC-USD

Litecoin

$ 187.713

3.17B

8.24B

12.52B

XRP-USD

XRP

$ 0.573

9.97B

7.83B

26.02B

BCH-USD

Bitcoin Cash

$ 526.676

3.13B

5.91B

9.84B

ADA-USD

Cardano

$ 1.161

5.21B

5.50B

37.10B

LINK-USD

Chainlink

$ 27.447

1.27B

4.58B

11.38B

EOS-USD

EOS

$ 4.158

2.29B

3.73B

3.96B

BNB-USD

BinanceCoin

$ 261.175

2.59B

2.58B

40.36B

DOGE-USD

Dogecoin

$ 0.055

1.27B

2.53B

7.14B

     *Prices as of March 23 @10:15 AM

 More info on cryptocurrency investing: 

Cryptocurrency Gaining Banks Acceptance

How Close is the U.S. to Having a Digital Currency?

Small-Cap Names in a Big Crypto Market

Backed by the Full Faith and Credit of Blockchain

Visit the Company data of Channelchek to review stocks on your watchlist in the blockchain category or any other that you have been following.

Comstock Mining (LODE) – First Mercury Remediation System is Up and Running in the Philippines

Wednesday, March 24, 2021

Comstock Mining (LODE)
First Mercury Remediation System is Up and Running in the Philippines

Comstock Mining Inc. is an emerging innovator and leader in the sustainable extraction, valorization, and production of scarce natural resources, with a focus on high value strategic materials that are essential to meeting the rapidly increasing global demand for clean energy, carbon-neutrality, and natural products.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First mercury remediation system operational in the Philippines. Comstock’s Clean Mercury Remediation Technologies (CMRT) joint venture with Mercury Clean Up LLC put the first commercial mercury remediation system into operation last week in Davao D’ Oro, Philippines. The unit has been deployed to recover and safely dispose of mercury from the Naboc River, along with recovering gold. According to Comstock management, the Head of the Philippine Department of Environment and Natural Resources (DENR), the country’s leading environmental regulator, stated that the Naboc River clean-up, if successful, could serve as a blueprint for treating other mercury contaminated areas in the country.

    A significant growth opportunity.  The mercury remediation system, operating at up to 150 tons per hour, is the first of several planned in the region. Each system, well-suited for remote deployment, remediates mercury while extracting by-products, including gold, cleaned sand, soil and gravel for commercial use. The company plans to deploy another system this year and several additional systems …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.